IDEntification of New Predisposition Genes in Differentiated THYroid Cancer

Differentiated Thyroid Cancer Clinical Trial

— IDENTHY-K  

Official title:

IDEntification of New Predisposition Genes in Differentiated THYroid Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05014698
• Other study ID #: RC19_0414
• Status: Active, not recruiting
• Phase: N/A
• Start date: February 23, 2022
• Est. completion date: February 2026

Study information

• Verified date: June 2024
• Source: Nantes University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this research is to find new predisposition genes for differentiated thyroid cancer (DTC).

Description:

The purpose of this research is to find new predisposition genes for differentiated thyroid cancer (DTC). Therefore, in the absence of a BAP1 and DICER1 abnormality, we offer to sequence your whole genome (WGS) or partial genome (genotyping) for a previously unknown genetic abnormality.

Furthermore, the discovery of new genes would be a major medical advance that could contribute to the identification of new therapeutic targets.

This research will be conducted at the University Hospital of Nantes and the Hospital of Vendée and 95 people should participate.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 34
• Est. completion date: February 2026
• Est. primary completion date: February 2026
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 8 Years and older

Eligibility

Inclusion Criteria:

• Probant subjects

• Minor or adult subject

• Adult subject or legal guardian for minor subjects agreeing to sign the study consent and biospecimen consent

• Subject with differentiated thyroid cancer without an identified causative mutation in the BAP1 and DICER 1 predisposition genes

• Patient affiliated to a valid social security plan

Relative subjects

• Adult subjects

• Subject agreeing to sign the study consent and the biocollection consent

• Subject with differentiated thyroid cancer or from a family with several cases of differentiated thyroid cancer without a causal mutation identified in the BAP1 and DICER 1 predisposition genes

• Patient affiliated to a social security plan

Exclusion Criteria:

• Subject refusing to participate

• Subjects with a causal mutation identified in the predisposition genes: BAP1 and DICER 1

• Subjects under guardianship, curatorship or safeguard of justice or not socially insured

• Subjects with another syndromic predisposition to thyroid cancer (Cowden, Werner, PAF)

Related Conditions & MeSH terms

• Differentiated Thyroid Cancer
• Disease Susceptibility
• Thyroid Diseases
• Thyroid Neoplasms

Intervention

Genetic:
• WGS
Whole Genome sequencing

Locations

Country	Name	City	State
France	Vendée Hospital	La Roche-sur-Yon
France	Nantes University Hospital	Nantes

Sponsors (1)

Lead Sponsor	Collaborator
Nantes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Type and Number of genetic variants associated with or causing the development of differentiated thyroid cancer	To be achieved by a whole genome sequencing (WGS) approach in a familial analysis of patients with differentiated thyroid cancer. In addition, high-throughput genotyping of multiple individuals in each family will allow complementary detection of genomic regions that are shared only by affected subjects	within 2 years
Secondary	Number of phenotypes associated to genotypes of CDT	By studying the association between the clinical characteristics of patients and the identified genetic variants	within 2 years
Secondary	Analysis of birthplace/family origin information	Definition of the spatial location of family forms of CDT and to identify possible founding effects	within 2 years